Hemostemix Inc.

Recent News

  • Hemostemix Announces Dr. Fraser C. Henderson Sr., MD, as Chief Medical Officer

    Calgary, Alberta--(Newsfile Corp. - October 14, 2021) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) (FSE: 2VFO) ("Hemostemix" or the "Company") is pleased to announce the appointment of Dr. Fraser C. Henderson Sr., MD, as its Chief Medical Officer.Dr. Fraser C. Henderson Sr. is an exceptional neurological surgeon with extensive experience and expertise in all facets of neurosurgery and neurological science. Dr. Henderson is Director of The Metropolitan Neurosurgery Group, LLC, Chief of Neurosurgery at Luminis Health at Doctors Hospital,...

    2021-10-14 9:15 AM EDT
  • Hemostemix Announces the Second Stem Cell Recipient Interview: One Week to No Chest Pain

    Calgary, Alberta--(Newsfile Corp. - October 4, 2021) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) ("Hemostemix" or the "Company") is pleased to announce the second in its series of video interviews with ACP-01 recipients taped during August of 2021. With more than 300 patients treated compassionately with ACP-01 for ischemic cardiomyopathy, dilated cardiomyopathy, vascular dementia, COPD, and pulmonary hypertension, in this one-minute segment Peter recounts how his chest pain dissipated one week after his stem cell treatment, and he recounts how...

    2021-10-04 2:05 PM EDT
  • Hemostemix Announces Closing of First Tranche of Unit Private Placement

    Calgary, Alberta--(Newsfile Corp. - September 21, 2021) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) ("Hemostemix" or the "Company") announces it has closed a first tranche of its previously announced non-brokered private placement of units ("Units") announced on September 8, 2021, for gross proceeds of $373,500 (the "Offering"). The Offering consisted of the issuance of an aggregate of 1,494,000 Units at a price of $0.25 per Unit. Each Unit consists of one common share in the capital of the...

    2021-09-21 9:21 AM EDT
  • Hemostemix Announces the First of a Series of 2021 Video Interviews with ACP-01 Recipients: What the Successful Compassionate Treatment of Ischemic Cardiomyopathy Looks Like After 13 Years

    Calgary, Alberta--(Newsfile Corp. - September 14, 2021) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) ("Hemostemix" or the "Company") is pleased to announce the first of a series of video interviews with ACP-01 recipient-patients taped during August of 2021. Treated compassionately with ACP-01 for ischemic cardiomyopathy, dilated cardiomyopathy, chronic obstructive pulmonary disease and vascular dementia, each recipient of the ACP-01 treatment recounts in full detail their return to a quality of life they thought was lost forever. In the first three-minute...

    2021-09-14 9:10 AM EDT
  • Hemostemix Announces Five Million Unit Private Placement

    Calgary, Alberta--(Newsfile Corp. - September 8, 2021) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) ("Hemostemix" or the "Company") is pleased to announce a non-brokered private placement for gross proceeds of up to $1,250,000 (the "Offering"). The Offering will consist of the issuance of an aggregate of up to 5,000,000 units ("Units") at a price of $0.25 per Unit. Each Unit consists of one common share in the capital of the Company ("Common Share") and one common share purchase...

    2021-09-08 4:54 PM EDT
  • Hemostemix Provides Update of Phase II Clinical Trial, 9th Circuit Court Decision Including Cost Award and its Annual General Meeting Results

    Calgary, Alberta--(Newsfile Corp. - July 6, 2021) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) ‎‎(FSE: 2VFO) ("Hemostemix" or the "Company") is pleased to provide an update on the Phase II Clinical Trial, an update of a decision including a cost award from the Ninth Judicial Circuit Court of Orange County, Florida, and the Annual General Meeting ("AGM") results.Hemostemix is continuing to complete the groundwork necessary to derive its Phase II Clinical Trial analyses. The process to rescue the trial has...

    2021-07-06 6:22 PM EDT
  • Hemostemix Announces Warrant Repricing and Extension

    Calgary, Alberta--(Newsfile Corp. - July 5, 2021) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) ‎‎(FSE: 2VFO) ("Hemostemix" or the "Company") is pleased to announce, subject to TSX Venture Exchange Approval, that it has extended for two years and repriced to $0.55 from $1, subject to the accelerator provisions stated below on all repriced warrants, 1,332,500 Warrants expiring July 9, 2021; extended 918,450 Warrants expiring November 24, 2021 of which 510,295 Warrants are repriced to $0.55 (408,155 Warrants held by insiders...

    2021-07-05 6:25 PM EDT
  • Peter Lacey Increases His Investment in Hemostemix Inc.

    Calgary, Alberta--(Newsfile Corp. - June 21, 2021) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) ‎‎(FSE: 2VFO) ("Hemostemix" or the "Company") announced today that, further to its June 11, 2021 news release and pursuant to the closing of the offering of debenture units of the Company ("Debenture Units"), Peter Lacey, a director and Chair of Hemostemix, acquired the 2,500 Debenture Units. Each Debenture Unit consisted of a $1,000 principal amount debenture (each, a "Debenture") and 2,500 common share purchase warrants ("Debenture...

    2021-06-21 10:01 PM EDT